Timothy M. Shannon net worth and biography

Timothy Shannon Biography and Net Worth

Director of Arvinas

Dr. Shannon is the Chairman of the Board of Arvinas and a Venture Partner at Canaan Partners. He also serves on the boards of Canaan portfolio companies IDEAYA Biosciences, Nextcure, Spyryx Biosciences, Vivace Therapeutics, and VaxInnate Corporation.

Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine.

Dr. Shannon received his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University. He earned his medical degree from the University of Connecticut and has a B.A. in Chemistry from Amherst College.

What is Timothy M. Shannon's net worth?: The estimated net worth of Timothy M. Shannon is at least $6,080.92 as of November 15th, 2016. Dr. Shannon owns 268 shares of Arvinas stock worth more than $6,081 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Shannon may own. Learn More about Timothy M. Shannon's net worth.
How do I contact Timothy M. Shannon?: The corporate mailing address for Dr. Shannon and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]. Learn More on Timothy M. Shannon's contact information.
Has Timothy M. Shannon been buying or selling shares of Arvinas?: Timothy M. Shannon has not been actively trading shares of Arvinas during the past quarter. Most recently, Timothy M. Shannon sold 36,411 shares of the business's stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $89.09, for a transaction totalling $3,243,855.99. Learn More on Timothy M. Shannon's trading history.
Who are Arvinas' active insiders?: Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?: In the last year, insiders at the sold shares 3 times. They sold a total of 8,597 shares worth more than $404,488.85. The most recent insider tranaction occured on February, 23rd when CEO John G Houston sold 5,196 shares worth more than $244,471.80. Insiders at Arvinas own 5.2% of the company. Learn More about insider trades at Arvinas.
Information on this page was last updated on 2/23/2024.

Timothy M. Shannon Insider Trading History at Arvinas

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/7/2021	Sell	36,411	$89.09	$3,243,855.99
9/3/2021	Sell	32,387	$85.53	$2,770,060.11
8/31/2021	Sell	59,355	$85.56	$5,078,413.80
8/27/2021	Sell	45,026	$85.42	$3,846,120.92
8/23/2021	Sell	1,599	$88.01	$140,727.99
6/17/2020	Buy	2,000	$30.26	$60,520.00
6/2/2020	Buy	3,000	$32.88	$98,640.00
3/20/2020	Buy	2,500	$35.13	$87,825.00
3/28/2019	Buy	3,500	$14.69	$51,415.00

Timothy M. Shannon Buying and Selling Activity at Arvinas

Arvinas Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $22.69

$21.17

$22.71

50 Day Range

MA: $25.62

$21.64

$28.04

2 Week Range

Now: $22.69

$20.28

$53.08

Volume

744,090 shs

Average Volume

711,069 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.